Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:GANXNASDAQ:GNFTNASDAQ:PROKNASDAQ:TNXP On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeGANXGain Therapeutics$1.78-0.8%$1.86$0.89▼$3.19$52.47M0.17310,956 shs122,296 shsGNFTGenfit$4.38-0.2%$3.80$2.55▼$6.42$218.98M0.9214,449 shs2,299 shsPROKProKidney$0.71-1.7%$0.78$0.46▼$4.28$207.35M1.5673,099 shs393,092 shsTNXPTonix Pharmaceuticals$39.80-5.3%$21.30$6.76▼$558.08$291.54M1.63888,370 shs1.57 million shs10 Stocks Set to Soar in Spring 2025Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Spring 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceGANXGain Therapeutics-0.28%0.00%-4.52%-15.73%-24.58%GNFTGenfit+2.20%+1.50%+8.63%+26.95%-15.77%PROKProKidney+2.08%-2.23%-33.29%-41.42%-81.81%TNXPTonix Pharmaceuticals+11.49%+59.17%+141.49%+434.61%-92.35%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationGANXGain Therapeutics2.5938 of 5 stars3.64.00.00.03.00.00.6GNFTGenfit2.1845 of 5 stars3.55.00.00.02.10.00.0PROKProKidney2.2762 of 5 stars3.30.00.00.02.74.20.6TNXPTonix Pharmaceuticals3.682 of 5 stars3.54.00.00.03.03.31.3Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceGANXGain Therapeutics 3.17Buy$8.20361.97% UpsideGNFTGenfit 3.00Buy$13.00196.80% UpsidePROKProKidney 2.50Moderate Buy$5.00605.82% UpsideTNXPTonix Pharmaceuticals 3.00Buy$585.001,369.85% UpsideCurrent Analyst Ratings BreakdownLatest GANX, TNXP, GNFT, and PROK Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/19/2025GANXGain TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$8.00 ➝ $8.003/28/2025GANXGain TherapeuticsChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$6.00 ➝ $6.003/20/2025TNXPTonix PharmaceuticalsNoble FinancialSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform$70.00 ➝ $70.003/17/2025GANXGain TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$8.00 ➝ $8.003/7/2025GANXGain TherapeuticsScotiabankSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageSector Perform ➝ Sector Outperform$12.00(Data available from 5/30/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookGANXGain Therapeutics$50K1,049.31N/AN/A$0.97 per share1.83GNFTGenfit$67.00M3.27N/AN/A$1.48 per share2.96PROKProKidney$306K677.61N/AN/A($4.84) per share-0.15TNXPTonix Pharmaceuticals$10.04M29.03N/AN/A$5,751.80 per share0.01Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateGANXGain Therapeutics-$22.27M-$0.86N/AN/AN/AN/A-203.91%-128.05%8/14/2025 (Estimated)GNFTGenfit-$31.27MN/A0.00N/AN/AN/AN/AN/A7/24/2025 (Estimated)PROKProKidney-$35.47M-$0.60N/AN/AN/AN/AN/A-10.24%8/8/2025 (Estimated)TNXPTonix Pharmaceuticals-$116.66M-$1,963.61N/AN/AN/A-1,197.86%-163.95%-118.88%8/15/2025 (Estimated)Latest GANX, TNXP, GNFT, and PROK EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/14/2025Q1 2025GANXGain Therapeutics-$0.16-$0.16N/A-$0.16$0.03 millionN/A5/12/2025Q1 2025PROKProKidney-$0.16-$0.13+$0.03-$0.13N/A$0.23 million5/12/2025Q1 2025TNXPTonix Pharmaceuticals-$3.23-$2.84+$0.39-$2.84$2.55 million$2.43 million3/27/2025Q4 2024GANXGain Therapeutics-$0.18-$0.11+$0.07-$0.11N/AN/A3/18/2025Q4 2024TNXPTonix Pharmaceuticals-$6.23-$9.77-$3.54-$9.77$3.20 million$2.58 million3/17/2025Q4 2024PROKProKidney-$0.14-$0.17-$0.03-$0.17N/A$0.08 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthGANXGain TherapeuticsN/AN/AN/AN/AN/AGNFTGenfitN/AN/AN/AN/AN/APROKProKidneyN/AN/AN/AN/AN/ATNXPTonix PharmaceuticalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioGANXGain Therapeutics0.042.992.99GNFTGenfit0.613.743.74PROKProKidneyN/A17.0817.09TNXPTonix Pharmaceuticals0.073.332.81Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipGANXGain Therapeutics11.97%GNFTGenfit2.24%PROKProKidney51.59%TNXPTonix Pharmaceuticals82.26%Insider OwnershipCompanyInsider OwnershipGANXGain Therapeutics7.18%GNFTGenfit4.20%PROKProKidney41.49%TNXPTonix Pharmaceuticals0.03%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableGANXGain Therapeutics2029.56 million23.42 millionOptionableGNFTGenfit12050.00 million47.90 millionNot OptionablePROKProKidney3292.70 million170.65 millionOptionableTNXPTonix Pharmaceuticals507.33 million1.87 millionNot OptionableGANX, TNXP, GNFT, and PROK HeadlinesRecent News About These CompaniesTonix Pharmaceuticals: August PDUFA Date For Fibromyalgia Med A Risky BetMay 30 at 4:21 PM | seekingalpha.comTonix Pharmaceuticals (NASDAQ:TNXP) Trading Down 3.6% - Here's WhyMay 30 at 1:38 PM | marketbeat.comZacks Small Cap Brokers Boost Earnings Estimates for TNXPMay 30 at 5:52 AM | marketbeat.comTonix Pharmaceuticals (NASDAQ:TNXP) Shares Up 9.1% - Should You Buy?May 29 at 2:08 PM | marketbeat.comJane Street Group LLC Purchases 1,635,119 Shares of Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP)May 29 at 3:05 AM | marketbeat.comWhat's Going On With Tonix Pharmaceuticals Stock?May 28 at 3:41 PM | benzinga.comTonix Pharmaceuticals (NASDAQ:TNXP) Stock Price Down 6% - Time to Sell?May 28 at 3:16 PM | marketbeat.comTNXP: Preparations Continue for Potential Commercial Launch of TNX-102 SL in Fibromyalgia…May 28 at 1:27 PM | finance.yahoo.comTonix Pharmaceuticals (NASDAQ:TNXP) Shares Up 9% - Here's WhyMay 27 at 2:34 PM | marketbeat.comTonix Pharmaceuticals (NASDAQ:TNXP) Trading 2.8% Higher - Still a Buy?May 25, 2025 | marketbeat.comPoint72 Asset Management L.P. Makes New $526,000 Investment in Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP)May 25, 2025 | marketbeat.comTonix Pharmaceuticals (NASDAQ:TNXP) Upgraded at Wall Street ZenMay 24, 2025 | marketbeat.comTonix Pharmaceuticals CEO Seth Lederman Participates in A.G.P. Annual Healthcare Company ShowcaseMay 22, 2025 | quiverquant.comTonix Pharmaceuticals Announces Presentation at the A.G.P. Annual Healthcare Company ShowcaseMay 22, 2025 | globenewswire.comTonix Pharmaceuticals Announces First Patient Dosed in Phase 2 OASIS Study of TNX-102 SL for Reduction of Acute Stress ReactionMay 21, 2025 | globenewswire.comTonix Pharmaceuticals (NASDAQ:TNXP) Shares Pass Above 200-Day Moving Average - Here's WhyMay 17, 2025 | marketbeat.comTonix Pharmaceuticals (TNXP) Stock Surges Following Insider Buying And Q1 ResultsMay 16, 2025 | benzinga.comInsider Buying: Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) CEO Purchases 4,000 Shares of StockMay 16, 2025 | insidertrades.comWhy Tonix Pharmaceuticals Holding Corp.’s (TNXP) Stock Is Up 5.05%May 15, 2025 | aaii.comTonix Pharma Stock Soars After Roping In Former Celgene Corp Executive Joseph Hand: Retail Gets More PositiveMay 15, 2025 | msn.comTonix Pharmaceuticals (NASDAQ:TNXP) Releases Earnings Results, Beats Expectations By $0.39 EPSMay 14, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeGANX, TNXP, GNFT, and PROK Company DescriptionsGain Therapeutics NASDAQ:GANX$1.78 -0.02 (-0.84%) Closing price 04:00 PM EasternExtended Trading$1.80 +0.02 (+1.13%) As of 06:05 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Gain Therapeutics, Inc., a biotechnology company, develops novel small molecule therapeutics to treat diseases across various therapeutic areas. Its drug discovery platform Magellan discovers novel allosteric binding sites in a disease; identifies proprietary small molecules that bind these sites to modulate protein function; and treats the underlying cause of the disease. The company's lead drug candidate, GT-02287 for the treatment of GBA1 Parkinson's disease is being evaluated in a Phase I clinical trials. It also has various small molecule drug candidates, which are in the discovery, research, and preclinical stages for the treatment of Dementia with Lewy Bodies, Alzhiemer's Disease, Gaucher, GM1 Gangliosidosis, Krabbe Disease, Alpha1-Antitrypsun deficiency, and solid tumors. Gain Therapeutics, Inc. was founded in 2017 and is headquartered in Bethesda, Maryland.Genfit NASDAQ:GNFT$4.38 -0.01 (-0.23%) Closing price 03:56 PM EasternExtended Trading$4.31 -0.07 (-1.58%) As of 04:01 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Genfit S.A., a late-stage biopharmaceutical company, discovers and develops drug candidates and diagnostic solutions for metabolic and liver-related diseases. The company develops Elafibranor, which is in Phase III clinical trial to treat patients with primary biliary cholangitis. It also engages in the development of NIS4 technology for the diagnosis of nonalcoholic steatohepatitis (NASH) and fibrosis; VS-01 for the treatment of Urea Cycle Disorder (UCD) and Organic Acidemia Disorder (OAD); GNS561, which is in Phase 1b/2a trial to treat patients with cholangiocarcinoma (CCA); VS-01-ACLF and Nitazoxanide (NTZ), which is in Phase 1 trial to treat acute-on-chronic liver failure, as well as VS-02-HE, which is in preclinical trial for the treatment of Reduction of Hyperammonemia and the Stabilization of Blood Ammonia; CML-022; SRT-015, an ASK1 inhibitor targets the inhibition of cellular apoptosis, inflammation, and fibrosis. The company has a licensing agreement with Labcorp for the commercialization of NASHnext, a blood-based molecular diagnostic test; and Genoscience Pharma to develop and commercialize the investigational treatment GNS561 for CCA. The company was incorporated in 1999 and is headquartered in Loos, France.ProKidney NASDAQ:PROK$0.71 -0.01 (-1.68%) Closing price 04:00 PM EasternExtended Trading$0.75 +0.04 (+6.30%) As of 05:38 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.ProKidney Corp., a clinical-stage biotechnology company, provides transformative proprietary cell therapy platform for treating various chronic kidney diseases in the United States. The company's lead product is Renal Autologous Cell Therapy (REACT), an autologous homologous cell admixture, which has completed Phase I clinical trial for REACT in patients with congenital anomalies of the Kidney and Urinary Tract (CAKUT), as well as in Phase III and Phase II clinical trials for the treatment of moderate to severe diabetic kidney disease. ProKidney Corp. founded in 2015 and is headquartered in Winston-Salem, North Carolina.Tonix Pharmaceuticals NASDAQ:TNXP$39.80 -2.22 (-5.28%) Closing price 04:00 PM EasternExtended Trading$38.51 -1.29 (-3.24%) As of 06:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Tonix Pharmaceuticals Holding Corp., a biopharmaceutical company, focuses on developing, discovering, commercializing, and licensing therapeutics to treat and prevent human disease and alleviate suffering. It markets Zembrace SymTouch and Tosymra for the treatment of acute migraine with or without aura in adults. Its portfolio focuses on central nervous system disorders, as well as rare disease, immunology, and infectious disease product candidates. The company's priority is to submit a New Drug Application (NDA) to the FDA for TNX-102 SL (cyclobenzaprine HCl sublingual tablet), which has completed two positive Phase 3 studies for the management of fibromyalgia. TNX-102 SL is also being developed to treat fibromyalgia-type Long COVID, a chronic post-acute COVID-19 condition. Its TNX-1300 (cocaine esterase) is a biologic designed to treat cocaine intoxication and has been granted breakthrough therapy designation by the FDA. The company's rare disease development portfolio comprises TNX-2900, an intranasal potentiated oxytocin for the treatment of Prader-Willi syndrome (PWS). Its immunology portfolio includes TNX-1500, which is a biologic to address organ transplant rejection and autoimmune diseases. The company's infectious disease pipeline includes TNX-801, a vaccine in development to prevent smallpox and mpox. TNX-801 also serves as the live virus vaccine platform or recombinant pox vaccine platform for other infectious diseases, including TNX-1800 and TNX-1850, in development as a vaccine to protect against COVID-19. Its infectious disease development portfolio also comprises TNX-3900, and TNX-4200 are orally available CD45 antagonists in preclinical development. Tonix Pharmaceuticals Holding Corp. has collaboration agreement with Bilthoven Biologicals to advance TNX-801 mpox vaccine candidate; and with X-Chem, Inc. to develop broad-spectrum antivirals. The company was founded in 2007 and is headquartered in Chatham, New Jersey. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Super Micro Computer Stock Finding Upside With NVIDIA's Blackwell Ackman Takes a Swing at Amazon — Should You? Taiwan Semiconductor: Time to Buy After Strong NVIDIA Results? Intel’s Turnaround May Be the Best Bet No One’s Watching Nike’s Amazon Expansion Could Signal a Turnaround in 2025 ASML Stock Might Be the Safest Chip Play at This Price Archer Aviation Stock Steadies After Short-Seller Report e.l.f. Beauty Sees Record Surge After Earnings, Rhode Deal Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
